Title: Production of Alpha Emitting Radionuclides for Nuclear Medicine
Publisher: European Commission - Joint Research Centre - Institute for Transuranium Elements
Publication Year: 2008
JRC N°: JRC48835
ISBN: 978-92-79-09115-5
ISSN: 1018-5593
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC48835
DOI: 10.2789/1900
Type: Articles in periodicals and books
Abstract: Targeted alpha therapy (TAT) is a novel approach for the treatment of cancer and infectious diseases based on the coupling of alpha particle emitting radioisotopes to target selective carrier molecules. Taking advantage of the short range (< 100 ¿m) and high linear energy transfer (LET ¿ 100 keV/¿m) of alpha particles in human tissue, targeted alpha therapy offers the potential of delivering a highly cytotoxic dose to targeted cells while minimizing damage to surrounding healthy tissue. The efficacy and safety of TAT has been shown in a number of pre-clinical studies and has to date been translated to clinical trials of leukemia, malignant melanoma, lymphoma, glioma, ovarian cancer and skeletal metastases [1-10]. For the further development and widespread application of TAT, the availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite. Here we describe the principle of TAT and give an overview on methods for the production of suitable radionuclides, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.